Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenalidomide + melphalan + prednisone + rituximab
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination is not a standard or approved therapy as detailed in the literature. Lenalidomide is an immunomodulatory drug used in multiple myeloma, myelodysplastic syndromes, and lymphomas. Melphalan is a chemotherapy agent, prednisone is a corticosteroid, and rituximab is a monoclonal antibody. The combination likely involves immunomodulatory, cytotoxic, anti-inflammatory, and monoclonal antibody mechanisms to target cancer cells.
02
Targets
CRBN (Cereblon)CD20 (B-lymphocyte antigen CD20)DNAIKZF3 (Zinc finger protein Aiolos)IKZF1 (Ikaros family zinc finger protein 1)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on lenalidomide + melphalan + prednisone + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenalidomide + melphalan + prednisone + rituximab.